Sanmai Technologies PBC: Developing Revolutionary Mental Health Treatments with Focused Ultrasound Neuromodulation
Addressing Unmet Mental Health Needs
Nowadays, mental health challenges are pervasive. Current treatment options often fall short of meeting the diverse needs of individuals suffering from anxiety and related disorders. Although traditional therapies, are beneficial for some, they do not provide the precision, efficacy, and speed required to effectively treat all patients. This gap highlights the urgent need for an innovation in mental health care.
Introducing Focused Ultrasound Neuromodulation for Precision Mental Health
At Sanmai, we are dedicated to creating a new option for clinicians to deliver treatment where needed. As the first Public Benefit Corporation in the field of neurotechnology, our mission is to develop advanced, non-invasive treatments that can precisely target and modulate brain activity to alleviate mental health challenges and make these treatments accessible. Our triple bottom line of people, planet, and profit drives our innovative approach with focused ultrasound neuromodulation. By adopting a triple bottom line approach, we seek to balance their economic goals with social responsibility and environmental stewardship. This holistic view of business performance encourages sustainable practices that benefit not Sanmai, but also society and the environment.
Sanmai’s Lotus Device
Sanmai is developing a pioneering medical device called Lotus, which uses low-intensity focused ultrasound neuromodulation to treat anxiety disorders. Scheduled for clinical trials in early 2025, Lotus is being rigorously tested for safety and efficacy. For current trials with our Gen0b prototype, we are collaborating with Acacia Clinics, a world-class research clinic known for its excellence in noninvasive brain stimulation for mental health and their previous success with the SAINT rTMS trials. With Acacia, we aim to provide robust evidence of our device’s therapeutic effects in a randomized, placebo-controlled trial.
Showcasing Innovation at BrainMind Summit
We recently had the privilege of making our public debut at the 2024 BrainMind Summit on Neuromodulation, BCI, and AI in New York City. This event brought together leading experts across science, technology, policy, and the arts, providing a platform to showcase our innovative technology. Our co-founder and CEO, Dr. Jay Sanguinetti, discussed the mission and technology advancements of Sanmai, highlighting our potential to transform mental health care through focused ultrasound neuromodulation. Our engineers, Quentin Todd and Dr. Sarp Satir, performed demos of our headset and our Acoustic Planning Tool’s acoustic modeling capabilities.
Sanmai stands at the forefront of neuromodulation innovation, aiming to revolutionize anxiety treatment with our non-invasive, precise, and effective therapies. Our journey from stealth mode to clinical trials represents a leap forward in the field of medical neurotechnology, driven by our commitment to making focused ultrasound neuromodulation an accessible solution for anybody suffering from a mental health issue.
To learn more about our clinical trials, contact trials@researchtechne.com or visit our ClinicalTrials.gov page.